Philip Morris ZYN Facility Investment: $1.2B Aurora Hub

The Philip Morris ZYN facility investment now totals approximately $1.2 billion in planned capital expenditure from 2024 through 2028. PMI formally opened the 780,000-square-foot Aurora, Colorado campus on July 27, 2026, but production started before the opening ceremony: local reporting confirms that the plant was already making and shipping ZYN by February 2026. The 148-acre site serves U.S. demand and, according to PMI, will support exports to Asia, Latin America and the Caribbean.

• Investment: approximately $1.2 billion planned for 2024–2028, up from the $600 million project announced in 2024
• Current status: formally opened July 27, 2026; production and shipments began before the ceremony
• Scale: approximately 780,000 square feet on 148 acres, with about 500 direct jobs expected
• Purpose: U.S. production plus future export capacity
• Annual output: PMI has not disclosed a verified annual ZYN production figure for Aurora
• Regulatory context: 20 ZYN products received FDA marketing authorization in January 2025 and specific modified-risk orders in June 2026

Last fact-checked: August 3, 2026. Investment, employment and export figures are company announcements and include forward-looking plans.

From a $600M Project to a $1.2B Campus

The scale changed quickly. PMI announced the Aurora project in July 2024 as a $600 million investment. When the campus opened on July 27, 2026, the company described approximately $1.2 billion in total planned capital expenditure between 2024 and 2028. That is twice the original headline figure, but it is more precise to call it an expanded multiyear capital plan than a simple one-time doubling: the newer total includes land, manufacturing equipment, infrastructure, facility development and future production capabilities.

The investment total comes from PMI's July 2026 opening announcement and was separately reported by Reuters and Axios. Production timing needs a distinction the opening release did not make clearly: the Denver Business Journal photographed production and documented shipments in February 2026. July 27, 2026 was the formal opening, not the first day the site made product.

The physical footprint is substantial: approximately 780,000 square feet across 148 acres. PMI expects the campus to directly employ about 500 people across engineering, production, technical, quality-control and support roles. The 500 figure is a company employment target, not a statement that every position is already filled. Actual hiring and compensation should be checked against current job listings.

The project is therefore no longer only a proposal or a construction plan; it is an operating manufacturing asset with further capital spending planned through 2028. What the investment does not prove on its own is that every retailer will see uninterrupted stock, lower wholesale prices or automatic access to future ZYN variants.

A U.S. Production and Export Hub

Aurora combines production, packaging, warehousing and distribution at one site. According to PMI, the campus will move products throughout the United States while supporting future exports to markets across Asia, Latin America and the Caribbean. That dual purpose matters: the facility is neither purely domestic nor accurately described as an export-first operation.

Aurora also does not stand alone. PMI's Owensboro, Kentucky facility manufactures ZYN, while its Wilson, North Carolina facility produces HEETS for the IQOS tobacco-heating system. These are different product operations, so Wilson should not be described as another ZYN plant. The additional Aurora site broadens PMI's U.S. manufacturing footprint, but public disclosures do not show how orders are allocated among individual lines.

The verified shift is straightforward: a project announced at $600 million in 2024 became an approximately $1.2 billion capital plan through 2028. Production and shipments were confirmed by February 2026, and PMI formally opened the campus on July 27, 2026.

What FDA Authorization Means for ZYN

Factory capacity and legal marketing status are separate questions. A new tobacco product generally needs an FDA marketing order before it may be legally marketed in the United States. Building a factory does not authorize a new product, flavor, strength or material product modification.

For ZYN's current U.S. portfolio, however, the article must reflect the orders already issued. On January 16, 2025, the FDA authorized the marketing of 20 specific ZYN products through the PMTA pathway. The orders cover ten named varieties in 3 mg and 6 mg strengths; they do not apply automatically to every ZYN product or to the nicotine-pouch category as a whole.

On June 30, 2026, the FDA issued modified risk granted orders for those 20 products. JAMA independently summarized the same 20-product decision and the 3 mg and 6 mg strengths. The orders allow one specific risk-modification claim comparing the use of ZYN instead of cigarettes; FDA separately explains that complete switching is the relevant harm-reduction context. The orders do not mean ZYN is “FDA approved,” risk-free or authorized to make any health claim it chooses. They expire after five years unless renewed, and FDA can withdraw them if the statutory standard is no longer met.

So PMTA remains a gatekeeper for new nicotine-pouch products and material changes, while the 20 named ZYN products have already cleared that gate. MRTP is a separate, optional pathway governing the reduced-risk information that may be communicated about specific authorized products.

What the Expansion Changes—and What It Does Not Prove

The Aurora campus adds domestic capacity, another production location and integrated warehousing and distribution. Those changes can improve operational flexibility and reduce dependence on a single plant. They also give PMI a U.S. base for future exports.

The public announcements do not disclose enough line-level capacity, order allocation or retailer inventory data to support a precise 12-month shelf-availability forecast. It would be speculation to promise fewer stockouts, lower prices or a particular metropolitan rollout. Retailers should treat the investment as evidence of added supply capacity, then rely on current distributor lead times, fill rates and authorized SKU lists for actual inventory planning.

The Bottom Line

The Philip Morris ZYN facility investment is a real expansion in U.S. manufacturing capacity, not merely a proposal on paper. Aurora is open, commercial production has begun and additional capital spending is planned through 2028. The campus is intended to serve U.S. demand and create future export capacity, but public information does not justify calling it export-first or predicting guaranteed retail availability.

The regulatory picture is equally specific. FDA authorization attaches to named products and claims, not to the factory or the category. As of August 3, 2026, 20 ZYN products have both U.S. marketing orders and authorization to use one specific modified-risk claim. Future products and material changes still require the applicable FDA review.

Age restriction: Under the federal Tobacco 21 law, U.S. retailers may not sell tobacco products, including nicotine pouches, to anyone under 21. Nicotine is addictive. People who do not currently use tobacco or nicotine products should not start.

Sources used for cross-checking: PMI — Aurora campus opening and $1.2 billion capital plan; Axios — site, employment and production timeline; Denver Business Journal — production and shipments before formal opening; Reuters — investment and export plan; PMI/Business Wire — original $600 million announcement; FDA — PMTA marketing authorization; FDA — modified risk granted orders; JAMA — independent regulatory summary.